Body Composition to Define Prognosis of Cancers Treated by Anti-Angiogenic Drugs.

adipose tissue angiogenesis inhibitor body composition computed tomography deep learning molecular targeted therapy muscle

Journal

Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402

Informations de publication

Date de publication:
05 Jan 2023
Historique:
received: 29 11 2022
revised: 28 12 2022
accepted: 03 01 2023
entrez: 21 1 2023
pubmed: 22 1 2023
medline: 22 1 2023
Statut: epublish

Résumé

Background: Body composition could help to better define the prognosis of cancers treated with anti-angiogenics. The aim of this study is to evaluate the prognostic value of 3D and 2D anthropometric parameters in patients given anti-angiogenic treatments. Methods: 526 patients with different types of cancers were retrospectively included. The software Anthropometer3DNet was used to measure automatically fat body mass (FBM3D), muscle body mass (MBM3D), visceral fat mass (VFM3D) and subcutaneous fat mass (SFM3D) in 3D computed tomography. For comparison, equivalent two-dimensional measurements at the L3 level were also measured. The area under the curve (AUC) of the receiver operator characteristics (ROC) was used to determine the parameters’ predictive power and optimal cut-offs. A univariate analysis was performed using Kaplan−Meier on the overall survival (OS). Results: In ROC analysis, all 3D parameters appeared statistically significant: VFM3D (AUC = 0.554, p = 0.02, cutoff = 0.72 kg/m2), SFM3D (AUC = 0.544, p = 0.047, cutoff = 3.05 kg/m2), FBM3D (AUC = 0.550, p = 0.03, cutoff = 4.32 kg/m2) and MBM3D (AUC = 0.565, p = 0.007, cutoff = 5.47 kg/m2), but only one 2D parameter (visceral fat area VFA2D AUC = 0.548, p = 0.034). In log-rank tests, low VFM3D (p = 0.014), low SFM3D (p < 0.0001), low FBM3D (p = 0.00019) and low VFA2D (p = 0.0063) were found as a significant risk factor. Conclusion: automatic and 3D body composition on pre-therapeutic CT is feasible and can improve prognostication in patients treated with anti-angiogenic drugs. Moreover, the 3D measurements appear to be more effective than their 2D counterparts.

Identifiants

pubmed: 36673015
pii: diagnostics13020205
doi: 10.3390/diagnostics13020205
pmc: PMC9858245
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Eur Urol Focus. 2018 Apr;4(3):420-434
pubmed: 28753824
Adv Exp Med Biol. 2017;1043:9-27
pubmed: 29224088
Diagnostics (Basel). 2021 Jan 18;11(1):
pubmed: 33477676
Invest Radiol. 2012 Dec;47(12):711-6
pubmed: 23095862
Int J Obes Relat Metab Disord. 1994 Apr;18(4):219-34
pubmed: 8044196
Eur J Cancer. 2022 Oct;174:90-98
pubmed: 35985252
Lancet. 2013 Jan 26;381(9863):295-302
pubmed: 23177515
J Nucl Med. 2016 May;57(5):753-8
pubmed: 26719376
Lancet Oncol. 2018 Mar;19(3):310-322
pubmed: 29449192
N Engl J Med. 2007 Jan 11;356(2):125-34
pubmed: 17215530
J Clin Oncol. 2002 Jan 1;20(1):289-96
pubmed: 11773181
Sci Rep. 2021 May 20;11(1):10628
pubmed: 34017035
Int J Cancer. 2021 Apr 1;148(7):1685-1694
pubmed: 33070307
NMR Biomed. 2015 May;28(5):583-90
pubmed: 25808071
J Clin Oncol. 2010 Feb 20;28(6):1054-60
pubmed: 20085939
Ann Oncol. 2011 Feb;22(2):295-300
pubmed: 20657034
J Digit Imaging. 2019 Apr;32(2):241-250
pubmed: 30756268
J Clin Oncol. 1999 Aug;17(8):2530-40
pubmed: 10561319
J Clin Oncol. 2009 Dec 1;27(34):5794-9
pubmed: 19826129
J Clin Oncol. 2016 Jan 10;34(2):144-50
pubmed: 26503203
Ann Oncol. 2010 Aug;21(8):1594-1598
pubmed: 20089558
Liver Cancer. 2019 Jul;8(4):255-270
pubmed: 31602369
IEEE Trans Neural Netw Learn Syst. 2022 Dec;33(12):6999-7019
pubmed: 34111009
Oncoimmunology. 2019 Mar 6;8(5):e1580128
pubmed: 31069139
Clin Nutr. 2021 Aug;40(8):5038-5046
pubmed: 34365038
Med Phys. 2022 Nov;49(11):7108-7117
pubmed: 35737963
Obesity (Silver Spring). 2012 Dec;20(12):2458-63
pubmed: 22728693
J Comput Assist Tomogr. 2018 Jan/Feb;42(1):139-145
pubmed: 28708717
Int J Obes Relat Metab Disord. 2003 Feb;27(2):211-8
pubmed: 12587001

Auteurs

Pierre Decazes (P)

Department of Medical Imaging and Nuclear Medicine, Henri Becquerel Cancer Center, 76038 Rouen, France.
QuantIF-LITIS (EA [Equipe d' Accueil] 4108), Faculty of Medicine, University of Rouen, 76000 Rouen, France.
Biomaps, UMR1281 INSERM, CEA, CNRS, University of Paris-Saclay, 94805 Villejuif, France.

Samy Ammari (S)

Biomaps, UMR1281 INSERM, CEA, CNRS, University of Paris-Saclay, 94805 Villejuif, France.
Department of Radiology, Gustave Roussy Cancer Campus, Université Paris-Saclay, 94800 Villejuif, France.

Antoine De Prévia (A)

Biomaps, UMR1281 INSERM, CEA, CNRS, University of Paris-Saclay, 94805 Villejuif, France.

Léo Mottay (L)

QuantIF-LITIS (EA [Equipe d' Accueil] 4108), Faculty of Medicine, University of Rouen, 76000 Rouen, France.

Littisha Lawrance (L)

Biomaps, UMR1281 INSERM, CEA, CNRS, University of Paris-Saclay, 94805 Villejuif, France.

Younes Belkouchi (Y)

Biomaps, UMR1281 INSERM, CEA, CNRS, University of Paris-Saclay, 94805 Villejuif, France.
CVN, CentraleSupélec, Inria, Université Paris-Saclay, 91190 Gif-Sur-Yvette, France.

Baya Benatsou (B)

Biomaps, UMR1281 INSERM, CEA, CNRS, University of Paris-Saclay, 94805 Villejuif, France.
Department of Radiology, Gustave Roussy Cancer Campus, Université Paris-Saclay, 94800 Villejuif, France.

Laurence Albiges (L)

Department of Cancer Medicine, Gustave Roussy Cancer Campus, Université Paris-Saclay, 94800 Villejuif, France.

Corinne Balleyguier (C)

Biomaps, UMR1281 INSERM, CEA, CNRS, University of Paris-Saclay, 94805 Villejuif, France.
Department of Radiology, Gustave Roussy Cancer Campus, Université Paris-Saclay, 94800 Villejuif, France.

Pierre Vera (P)

Department of Medical Imaging and Nuclear Medicine, Henri Becquerel Cancer Center, 76038 Rouen, France.
QuantIF-LITIS (EA [Equipe d' Accueil] 4108), Faculty of Medicine, University of Rouen, 76000 Rouen, France.

Nathalie Lassau (N)

Biomaps, UMR1281 INSERM, CEA, CNRS, University of Paris-Saclay, 94805 Villejuif, France.
Department of Radiology, Gustave Roussy Cancer Campus, Université Paris-Saclay, 94800 Villejuif, France.

Classifications MeSH